335 related articles for article (PubMed ID: 31953311)
1. Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival.
Pocha K; Mock A; Rapp C; Dettling S; Warta R; Geisenberger C; Jungk C; Martins LR; Grabe N; Reuss D; Debus J; von Deimling A; Abdollahi A; Unterberg A; Herold-Mende CC
Clin Cancer Res; 2020 May; 26(9):2231-2243. PubMed ID: 31953311
[TBL] [Abstract][Full Text] [Related]
2. SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma.
Yuan L; Wu X; Zhang L; Yang M; Wang X; Huang W; Pan H; Wu Y; Huang J; Liang W; Li J; Zhu X; Wang S; Guan J; Liu L
Cancer Immunol Immunother; 2022 Feb; 71(2):399-415. PubMed ID: 34181042
[TBL] [Abstract][Full Text] [Related]
3. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
[TBL] [Abstract][Full Text] [Related]
4. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
5. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
7. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
9. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
10. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
Zheng M; Liu J; Bian T; Liu L; Sun H; Zhou H; Zhao C; Yang Z; Shi J; Liu Y
Int Immunopharmacol; 2021 Jan; 90():107134. PubMed ID: 33168407
[TBL] [Abstract][Full Text] [Related]
11. NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.
Yan Y; Gao Z; Han H; Zhao Y; Zhang Y; Ma X; Chen H
J Cancer Res Clin Oncol; 2022 Mar; 148(3):565-575. PubMed ID: 34746975
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
Budczies J; Kirchner M; Kluck K; Kazdal D; Glade J; Allgäuer M; Kriegsmann M; Heußel CP; Herth FJ; Winter H; Meister M; Muley T; Goldmann T; Fröhling S; Wermke M; Waller CF; Tufman A; Reck M; Peters S; Schirmacher P; Thomas M; Christopoulos P; Stenzinger A
Cancer Immunol Immunother; 2022 Feb; 71(2):251-265. PubMed ID: 34125345
[TBL] [Abstract][Full Text] [Related]
13. ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma.
Miyashita N; Horie M; Mikami Y; Urushiyama H; Fukuda K; Miyakawa K; Matsuzaki H; Makita K; Morishita Y; Harada H; Backman M; Lindskog C; Brunnström H; Micke P; Nagase T; Saito A
Cancer Lett; 2020 Oct; 489():121-132. PubMed ID: 32534174
[TBL] [Abstract][Full Text] [Related]
14. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
[TBL] [Abstract][Full Text] [Related]
15. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
16. Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.
Kadota K; Yeh YC; Villena-Vargas J; Cherkassky L; Drill EN; Sima CS; Jones DR; Travis WD; Adusumilli PS
Chest; 2015 Sep; 148(3):711-721. PubMed ID: 25836013
[TBL] [Abstract][Full Text] [Related]
17. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
18. Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?
Kilvaer TK; Paulsen EE; Andersen S; Rakaee M; Bremnes RM; Busund LR; Donnem T
Carcinogenesis; 2020 Dec; 41(12):1671-1681. PubMed ID: 33035322
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
Koletsa T; Kotoula V; Koliou GA; Manousou K; Chrisafi S; Zagouri F; Sotiropoulou M; Pentheroudakis G; Papoudou-Bai A; Christodoulou C; Xepapadakis G; Zografos G; Petraki K; Pazarli E; Koutras A; Kourea HP; Bafaloukos D; Chatzopoulos K; Iliadis A; Markopoulos C; Venizelos V; Arnogiannaki N; Kalogeras KT; Kostopoulos I; Gogas H; Fountzilas G
Cancer Immunol Immunother; 2020 Aug; 69(8):1549-1564. PubMed ID: 32303794
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the immune microenvironment in brain metastases from different solid tumors.
Jiang J; Wu L; Yuan F; Ji J; Lin X; Yang W; Wu J; Shi M; Yang H; Ma Y; Song X; Zhu Z; Zhang H; Zhang J
Cancer Med; 2020 Apr; 9(7):2299-2308. PubMed ID: 32017467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
